Journal of the National Comprehensive Cancer Network : JNCCN · 2025
Olanzapine for Anorexia in Patients With Incurable Cancer and Cachexia (OlAnCa): A Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
СтатьяРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Othman Nada O, Abdel-Aal Hesham H, Elsherief Wessam A, Farag Dina E, Hunter Catherine N, Alsirafy Samy A
Аннотация
BACKGROUND: Pharmacologic options for managing anorexia in cancer cachexia are limited. This trial aimed to evaluate the efficacy of olanzapine in alleviating anorexia in patients with incurable cancer and cachexia.
METHODS: This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer and cachexia, scoring ≥4 on the Edmonton Symptom Assessment Scale (ESAS) anorexia item (ESAS-Anorexia) and <4 on the ESAS nausea item (ESAS-Nausea). A total of 164 patients were randomized in a 1:1 ratio to receive either placebo (n=82) or olanzapine 5 mg daily (n=82) for 4 weeks. The primary outcome was the change in ESAS-Anorexia score after 1 week. Secondary outcomes included changes in anorexia and quality of life scores, body weight, and handgrip strength after 4 weeks.
RESULTS: In the complete case analysis of the primary outcome (n=159; 97%), median [IQR] reduction in ESAS-Anorexia score after 1 week was significantly greater in the olanzapine group (-2 [-3 to 0] vs -1 [-2 to 0]; P=.003). The significance continued at 2 weeks (-2 [-4 to -1] vs -1 [-2 to 0]; P=.039). After 4 weeks, significantly more patients in the olanzapine group experienced >5% weight gain (14% vs 0%; P=.008), and the mean [SD] improvement in Functional Assessment of Anorexia/Cachexia Therapy - Anorexia/Cachexia Subscale score was higher (+2.7 [7.4] vs -0.04 [7]; P=.043). The mean [SD] decline in handgrip strength was greater with olanzapine and was significant in per-protocol analysis (-2.8 [4.9] kg vs -0.3 [4.1] kg; P=.027). Anxiety, insomnia, and nausea (P=.016, P=.034, and P=.039, respectively) were significantly less frequent with olanzapine, whereas grade ≥3 anemia and leukopenia were more frequent (P=.018 and P=.041, respectively).
CONCLUSIONS: A short course of olanzapine 5 mg daily significantly reduces anorexia in patients with incurable cancer and cachexia. Further studies are needed to evaluate its long-term safety and efficacy in cancer cachexia.
METHODS: This double-blind, placebo-controlled, randomized trial included adult patients with incurable cancer and cachexia, scoring ≥4 on the Edmonton Symptom Assessment Scale (ESAS) anorexia item (ESAS-Anorexia) and <4 on the ESAS nausea item (ESAS-Nausea). A total of 164 patients were randomized in a 1:1 ratio to receive either placebo (n=82) or olanzapine 5 mg daily (n=82) for 4 weeks. The primary outcome was the change in ESAS-Anorexia score after 1 week. Secondary outcomes included changes in anorexia and quality of life scores, body weight, and handgrip strength after 4 weeks.
RESULTS: In the complete case analysis of the primary outcome (n=159; 97%), median [IQR] reduction in ESAS-Anorexia score after 1 week was significantly greater in the olanzapine group (-2 [-3 to 0] vs -1 [-2 to 0]; P=.003). The significance continued at 2 weeks (-2 [-4 to -1] vs -1 [-2 to 0]; P=.039). After 4 weeks, significantly more patients in the olanzapine group experienced >5% weight gain (14% vs 0%; P=.008), and the mean [SD] improvement in Functional Assessment of Anorexia/Cachexia Therapy - Anorexia/Cachexia Subscale score was higher (+2.7 [7.4] vs -0.04 [7]; P=.043). The mean [SD] decline in handgrip strength was greater with olanzapine and was significant in per-protocol analysis (-2.8 [4.9] kg vs -0.3 [4.1] kg; P=.027). Anxiety, insomnia, and nausea (P=.016, P=.034, and P=.039, respectively) were significantly less frequent with olanzapine, whereas grade ≥3 anemia and leukopenia were more frequent (P=.018 and P=.041, respectively).
CONCLUSIONS: A short course of olanzapine 5 mg daily significantly reduces anorexia in patients with incurable cancer and cachexia. Further studies are needed to evaluate its long-term safety and efficacy in cancer cachexia.